Formerly known as Serenix Pharmaceuticals, LLC with the name-change to Azevan Pharmaceuticals, Inc. in early 2002, the firm is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. Developing new molecules that address significant unmet needs in psychiatry through a novel mechanism of action, the Company leverages its expertise in behavioral neurobiology with its proprietary chemistry platform targeting G-protein coupled receptors (GPCRs) to create drug candidates. The Companys first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and Major Depression. Vasopressin receptor antagonists represent a novel mechanism of action for addressing these indications.
